HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E8130 TAT-14 TAT-14 is a 14-mer peptide that acts as Nrf2 activator with an anti-inflammatory effect. TAT-14 has no effect on Nrf2 mRNA expression, but increases Nrf2 protein level due to targeting the Nrf2 binding site on Keap1. Dec 20 2024
E5097 Tribuloside Tribuloside is a flavonoid that can be isolated from Tribulus terrestris L. Tribuloside exhibits anti-mycobacterial activity against the non-pathogenic Mycobacterium species with a minimum inhibitory concentration (MIC) of 5.0 mg/mL. Tribuloside has 1,1-diphenyl-2-picrylhydrazyl radical scavenging activity. Dec 20 2024
P1157 Z-FY-CHO Z-FY-CHO (Z-Phe-Tyr-CHO) is a potent and specific inhibitor of Cathepsin L (CTSL) that ameliorates cell apoptosis and preserves effective autophagic degradation. Dec 20 2024
E7619 VH032 VH032 is a VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. VH032 is a VHL/HIF-1α interaction inhibitor with a KdPROTACs. Dec 20 2024
E7875 Gypenoside LXXV Gypenoside LXXV, isolated from Gynostemma pentaphyllum, is one of the deglycosylated shapes of ginsenoside Rb1. Gypenoside LXXV significantly reduces cancer cell viability and displays an anti-cancer effect. Dec 20 2024
E8131 RI-2 RI-2 is a reversible RAD51 inhibitor, with an IC50 of 44.17 μM, and specifically inhibits homologous recombination repair in human cells. Dec 20 2024
E1592 Gepotidacin Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor. Dec 20 2024
E7620 Dibutyryl-cGMP sodium Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analogue. Dibutyryl-cGMP sodium preferentially activates cGMP-dependent protein kinase (PKG). Dibutyryl-cGMP sodium inhibits the release of [3H]-arachidonic acid from γ thrombin-stimulated human platelets. Dibutyryl-cGMP sodium induces peripheral antinociception via activation of ATP-sensitive K+ channels. Dec 20 2024
E7876 GPRP acetate GPRP acetate (Gly-Pro-Arg-Pro acetate) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa). Dec 20 2024
E8132 SRT3109 SRT3109 is an antagonist of CXCR2, with a pIC50 of 8.2, and used in the research of chemokine mediated diseases. Dec 20 2024
E8102 MRT68921 MRT68921 is a potent inhibitor of ULK1 and ULK2, with IC50 values of 2.9 nM and 1.1 nM, respectively. Dec 20 2024
E7621 5,6-Dihydrouridine 5,6-Dihydrouridine is a modified base found in conserved positions in the D-loop of tRNA in Bacteria, Eukaryota, and some Archaea. Dec 20 2024
E7877 MLCK inhibitor peptide 18 MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations. Dec 20 2024
E8133 Rhapontigenin 3'-O-glucoside Rhapontigenin 3'-O-glucoside is a derivative of Rhapontigenin. Rhapontigenin is a potent inactivator of human P450 1A1 and is a good candidate for a cancer chemopreventive agent. Dec 20 2024
E1278 ACHP Hydrochloride ACHP Hydrochloride (IKK-2 Inhibitor VIII) is a highly potent and selective IKK-β inhibitor with an IC50 of 8.5 nM. Dec 20 2024
E7622 LP-533401 LP-533401 is a Tryptophan hydroxylase 1 inhibitor that regulates serotonin production in the gut. Dec 20 2024
E7878 N-Bis(2-hydroxypropyl)nitrosamine N-Bis(2-hydroxypropyl)nitrosamine is an agent with carcinogenic activity. Dec 20 2024
E8134 Y-26763 Y-26763 is a K+ channel opener and active metabolite of Y-27152. Y-26763 is an ATP-sensitive K+ (KATP) channel activator. Dec 20 2024
S7882 BQ-788 BQ-788 is a potent, selective ETB receptor antagonist with IC50 of 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells, poorly inhibiting the binding to ETA receptors in human neuroblastoma cell line SK-N-MC cells with IC50 of 1300 nM. Dec 20 2024
E7623 Eglumegad Eglumegad (LY354740) is a highly potent and selective group II (mGlu2/3) receptor agonist with IC50s of 5 nM and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively. Dec 20 2024